$ANGX

B. Riley Lifts PT on Angel Studios (ANGX) – Here’s Why

B. Riley raised its price target on Angel Studios (NYSE:ANGX) to $8 from $7 and kept a Buy rating on June 30. The firm cited higher fiscal Q2 estimates tied to paying Guild members and said Angel Studios may benefit from an improved film slate, including Young Washington’s theater debut. Angel Studios reported fiscal Q1 2026 revenue up 143% to $115.1 million.

Original reporting
Published Jul 16, 2026, 7:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 16, 2026, 7:20 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
B. Riley Lifts PT on Angel Studios (ANGX) – Here’s Why — source image
Decision brief

The 30-second read

$ANGXBullishMed
01

Why it matters

The immediate tradable element is the analyst PT increase and estimate lift, which can influence positioning and sentiment, especially if the upcoming theater debut is expected to drive engagement.

02

Market read

A concrete analyst PT raise and near-term estimate lift for ANGX, plus a near-term entertainment catalyst tied to a specific film release.

03

What to watch

The article does not quantify the magnitude of the estimate changes beyond citing higher paying Guild members, so traders should verify whether the underlying KPIs are durable beyond Q2.

Relevance 7/10Novelty 6/10Timing: post-note, ahead of the next film release catalyst mentioned (Young Washington)

Background

Angel Studios is described as a values-based distribution company for stories, with B. Riley citing higher fiscal Q2 paying Guild members and a better film slate.

Company-level read

Ticker impact

$ANGXBullishMedium confidence
Context

B. Riley raised Angel Studios’ price target to $8 from $7 and lifted near-term estimates citing higher fiscal Q2 paying Guild members.

Expected impact

Mildly positive bias for the stock near-term, with follow-through dependent on whether the film slate catalyst translates into subscriber or revenue momentum.

Evidence & confidence

The article provides a concrete PT change and estimate revision, but it is still an analyst note rather than a new company filing or earnings print.

Market effects

Supports sentiment for small-cap entertainment/story distribution names if paying-member growth is improving.

None indicated.

None indicated.

Counterpoint

The catalyst is a film release and the PT change is analyst-driven, so near-term upside may be limited if Guild member growth or monetization does not follow through.

Key entities

  • Angel Studios, Inc.

    Subject of the analyst price-target increase and estimate lift; ticker ANGX.

  • B. Riley

    Raised ANGX price target to $8 from $7 and maintained Buy rating, citing higher paying Guild members.

  • Young Washington

    Scheduled to debut in theaters later this week, cited as a potential catalyst.

  • Comcast

    Mentioned only for its media and connectivity split as a 'pure play' value nod.

Related articles

$ANGXMed

Angel Reports Second Quarter 2026 Results: Guild Membership Climbs 99.2% Year-Over-Year

Angel Studios, Inc. (ANGX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Angel Reports Second Quarter 2026 Results: Guild Membership Climbs 99.2% Year-Over-Year ~ Guild Revenue of $90.7 Million, Up 93.8% Year-Over-Year ~ ~ Guild Selling & Marketing Expense Falls to 52.8% of Guild Revenue in Q2 2026, Reduced from 71.6% in Q2 2025 ~ ​ PROVO

$SYKMed

Stryker Names Spencer Stiles CEO as CMR Surgical Investment Advances

Stryker Corporation has appointed Spencer Stiles as its next CEO, effective January 1, 2027. Current CEO Kevin Lobo will become executive chair. The company also announced a $400 million investment in CMR Surgical to support its Versius surgical robotics portfolio. Stryker reported Q2 2026 revenue of $6.59 billion, a 9.40% increase year-over-year, with adjusted earnings per share of $3.69, exceeding estimates.